Neoadjuvant therapy for resectable pancreatic cancer: a narrative review

被引：1

作者：

Wang Chengfang ^{[1
,2
,3
,4
,5
]}

Wu Yingsheng ^{[1
,2
,3
,4
,5
]}

Wang Weilin ^{[1
,2
,3
,4
,5
]}

机构：

[1] Department of Hepatobiliary and Pancreatic Surgery

[2] The Second Affiliated Hospital

[3] Zhejiang University School of Medicine

[4] Hangzhou

[5] China

来源：

胰腺病学杂志（英文） | 2022年 / 05卷 / 02期

关键词：

Chemotherapy; Neoadjuvant therapy; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Preoperative therapy; Resectable pancreatic cancer;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 ;

摘要：

The use of neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma remains controversial and limited. Therefore, this literature review aimed to assess the feasibility, safety, and efficacy of this treatment. A database search of peer-reviewed articles published in English between January 1990 and June 2021 in PubMed, MEDLINE, and the Web of Science was performed. Original articles, review articles, and meta-analyses relevant to the topic were selected. We found 2 to 4 cycles with FOLFIRINOX, gemcitabine plus nab-paclitaxel, gemcitabine plus S-1, or gemcitabine alone were the most acceptable treatments. Considering the risk of adverse events and cancer progression, NAT is considered safe and tolerable, with a comparable resection rate. Although NAT can result in moderate tumor responses and some extent of local control (improvement of complete resection rate and negative lymph node metastases), no obvious survival benefit is observed. To date, the survival benefits of NAT for resectable pancreatic ductal adenocarcinoma have been very limited. It is too early to say that NAT is the best treatment option for resectable pancreatic cancer.

引用

共 76 条

[1]

Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer[J] . Strijker Marin,van der Sijde Fleur,Suker Mustafa,Boermeester Marja A,Bonsing Bert A,Bruno Marco J,Busch Olivier R,Doukas Michail,van Eijck Casper H,Gerritsen Arja,Groot Koerkamp Bas,Haj Mohammad Nadia,van Hilst Jony,de Hingh Ignace H,van Hooft Jeanin E,Luyer Misha D,Quintus Molenaar I,Verheij Joanne,Waasdorp Cynthia,Wilmink J

[2] Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer [J].

Imamura, Masafumi ;

Nagayama, Minoru ;

Kyuno, Daisuke ;

Ota, Shigenori ;

Murakami, Takeshi ;

Kimura, Akina ;

Yamaguchi, Hiroshi ;

Kato, Toru ;

Kimura, Yasutoshi ;

Takemasa, Ichiro .

CANCERS, 2021, 13 (10)

[3]

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J] . Tempero Margaret A,Malafa Mokenge P,AlHawary Mahmoud,Behrman Stephen W,Benson Al B,Cardin Dana B,Chiorean E Gabriela,Chung Vincent,Czito Brian,Del Chiaro Marco,Dillhoff Mary,Donahue Timothy R,Dotan Efrat,Ferrone Cristina R,Fountzilas Christos,Hardacre Jeffrey,Hawkins William G,Klute Kelsey,Ko Andrew H,Kunstman John W,LoConte Noelle,Lowy Andrew M,Moravek Cassadie,Nakakura Eric K,Narang Amol K,Obando Jorg

[4] Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer Propensity Score Matching [J].

Mie, Takafumi ;

Sasaki, Takashi ;

Takeda, Tsuyoshi ;

Fukuda, Koshiro ;

Furukawa, Takaaki ;

Yamada, Yuto ;

Kasuga, Akiyoshi ;

Matsuyama, Masato ;

Ozaka, Masato ;

Sasahira, Naoki .

PANCREAS, 2021, 50 (04) :595-601

[5] Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective [J].

Kurata, Yoshihiro ;

Shiraki, Takayuki ;

Ichinose, Masanori ;

Kubota, Keiichi ;

Imai, Yasuo .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)

[6] Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? [J].

Kim, Hyung Sun ;

Nakagawa, Kenji ;

Akahori, Takahiro ;

Nakamura, Kota ;

Takagi, Tadataka ;

Sho, Masayuki ;

Park, Joon Seong ;

Yoon, Dong Sup .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) :1-9

[7] A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer [J].

Tajima, Hidehiro ;

Makino, Isamu ;

Gabata, Ryosuke ;

Okazaki, Mitsuyoshi ;

Ohbatake, Yoshinao ;

Shimbashi, Hiroyuki ;

Nakanuma, Shinich ;

Saitoh, Hiroto ;

Shimada, Mari ;

Yamaguchi, Takahisa ;

Okamoto, Koichi ;

Moriyama, Hideki ;

Kinoshita, Jun ;

Nakamura, Keishi ;

Miyashita, Tomoharu ;

Ninomiya, Itasu ;

Fushida, Sachio ;

Ikeda, Hiroko ;

Ohta, Tetsuo .

MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (02) :1-7

[8]

Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the national Cancer database[J] . Greco Stephanie H.,August David A.,Shah Mihir M.,Chen Chunxia,Moore Dirk F.,Masanam Monika,Turner Amber L.,Jabbour Salma K.,Javidian Parisa,Grandhi Miral S.,Kennedy Timothy J.,Alexander H. Richard,Carpizo Darren R.,Langan Russell C..Surgery Open Science . 2020 (prep)

[9]

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma[J] . Ahmad Syed A,Duong Mai,Sohal Davendra P S,Gandhi Namita S,Beg Muhammad Shaalan,Wang-Gillam Andrea,Wade James L,Chiorean Elena Gabriela,Guthrie Katherine A,Lowy Andrew M,Philip Philip A,Hochster Howard S.Annals of surgery . 2020

[10] Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score [J].

Kim, Dong Wook ;

Lee, Seung Soo ;

Kim, Seon-Ok ;

Kim, Jin Hee ;

Kim, Hyoung Jung ;

Byun, Jae Ho ;

Yoo, Changhoon ;

Kim, Kyu-pyo ;

Song, Ki-Byung ;

Kim, Song Cheol .

RADIOLOGY, 2020, 296 (03) :541-551

← 1 2 3 4 5 6 7 8 →